Cite
HARVARD Citation
You, C. et al. (2021). Safety, pharmacokinetics, and pharmacodynamics of a next‐generation subcutaneously administered coagulation factor IX variant, dalcinonacog alfa, in previously treated hemophilia B patients. Journal of thrombosis and haemostasis. pp. 967-975. [Online].